title: Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide.
abstract: Mantle cell lymphoma is a hematologic malignancy characterized by poor therapeutic outcomes. Immunomodulatory drugs are a focus of attention in this disease, especially for the elderly and frail patients not able to tolerate the typically intensive therapeutic approaches used in fitter patients. We here present the case of refractory mantle cell lymphoma of the elderly that achieved complete remission following the use of single-agent lenalidomide, and a second complete response to the same regimen on relapse 5 years later.
authors.affiliation: Institute of Cancerology and Hematology, University Hospital, Brest, France.
authors.forename: Adrian
authors.initials: A
authors.lastname: Tempescul
authors.affiliation: Institute of Cancerology and Hematology, University Hospital, Brest, France.
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Ianotto
authors.affiliation: Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.|Laboratory of Immunology and Immunotherapy, University Hospital, Brest, France.
authors.forename: Cristina
authors.initials: C
authors.lastname: Bagacean
authors.affiliation: Nuclear Medicine Department, University Hospital, Brest, France.
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Salaun
authors.affiliation: Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
authors.forename: Corina
authors.initials: C
authors.lastname: Bocsan
authors.affiliation: Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. mzdrenghea@umfcluj.ro.|Ion Chiricuta Oncology Institute, Cluj-Napoca, Romania. mzdrenghea@umfcluj.ro.
authors.forename: Mihnea
authors.initials: M
authors.lastname: Zdrenghea
mesh_terms: D000368:Aged; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000077269:Lenalidomide; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D012008:Recurrence; D012074:Remission Induction / Q000379:methods; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide
keywords: IMiD; Lenalidomide; Mantle cell lymphoma; Relapse